Table
1: Patient
characteristics.
|
Characteristic |
N |
% |
|
Age |
||
|
Median, (range) |
64 (40-90) |
|
|
Subtype |
||
|
ER + and/or PgR + |
65 |
59% |
|
Triple Negative |
41 |
37% |
|
Unkown |
4 |
4% |
|
Dominant disease site |
||
|
Non-visceral |
28 |
25% |
|
Visceral |
82 |
75% |
|
Liver |
50 |
46% |
|
Lung and/or |
39 |
36% |
|
Central nervous system |
6 |
6% |
|
Prior lines of chemotherapy for
advanced disease |
||
|
Median, (range) |
3 (0-10) |
|
|
Number of prior chemotherapy for
advanced disease |
||
|
0 |
13 |
12% |
|
1 |
12 |
11% |
|
2 |
19 |
17% |
|
3 |
31 |
28% |
|
≥
4 |
35 |
32% |
|
Previous chemotherapy |
||
|
Anthracyclines |
86 |
78% |
|
Taxanes |
104 |
95% |
|
Dose of eribulin |
||
|
1.4 mg/m2 |
62 |
56% |
|
1.1 mg/m2 |
35 |
32% |
|
0.9 mg/m2 |
3 |
3% |
|
0.7 mg/m2 |
10 |
9% |
|
Clinical response |
||
|
Complete response |
1 |
1% |
|
Partial response |
20 |
18% |
|
Stable disease |
56 |
51% |
|
Overall response |
21 |
19% |
|
Clinical benefit |
34 |
34% |
|
Time to treatment failure |
||
|
3.4 months (95% CI; 2.77 - 4.10) |
||
|
Cause of treatment failure |
||
|
Progression Disease |
89 |
81% |
|
Adverse event |
8 |
7% |
|
Others |
3 |
3% |
ER: Estrogen Receptor;
PgR: Progesterone Receptor